Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in women with advanced en

[News]

Aeterna Zentaris Inc. today announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer.

More... (http://www.news-medical.net/news/20150630/Aeterna-Zentaris-recruits-patients-for-ZoptEC-Phase-3-study-in-women-with-advanced-endometrial-cancer.aspx)